Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 7/20 | 0.55 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483714 | 0.92 | PTPN1 (0.50) | GPR132PPARAPPARGPTPN1ACE | |
| SCHEMBL2714607 | 0.89 | PPARA (0.55) | PPARAPPARGPTPN1ACEPPARD | |
| SCHEMBL20876849 | 0.89 | PPARA (0.55) | PPARAPPARGPTPN1ACEPPARD | |
| SCHEMBL2727271 | 0.89 | PPARA (0.55) | PPARAPPARGPTPN1ACEPPARD | |
| SCHEMBL31407706 | 0.85 | PPARA (0.55) | GPR132PPARAPPARGPTPN1ACE | |
| SCHEMBL2864878 | 0.84 | PPARA (0.60) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL2864877 | 0.84 | PPARA (0.60) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL20835705 | 0.84 | PPARA (0.60) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL4650144 | 0.83 | PTPN1 (0.64) | GPR132PPARAPPARGPTPN1ACE | |
| SCHEMBL2552297 | 0.83 | PTPN1 (0.64) | GPR132PPARAPPARGPTPN1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1943216-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1934176-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042240-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | GPR132 302/4885PPARA 2593/4885PPARG 535/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | GPR132 454/4885PPARA 2551/4885PPARG 699/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | GPR132 439/4885PPARA 4528/4885PPARG 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.